SUBSCRIBE
SUBSCRIBE

OrsoBio

NEWS
NextGen
BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
 · 
5 min read
 · 
Heather McKenzie
IN THE PRESS
Deals
OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company
November 2, 2022
 · 
4 min read
Biotech Bay
OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders
November 2, 2022
 · 
3 min read
Biotech Bay
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders
November 2, 2022
 · 
4 min read
Biotech Bay
OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders
November 1, 2022
 · 
4 min read
Load More
AWARDS
  • NextGen Class of 2025
JOBS